Drug Trial Radar · NCT05931042
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
Last checked: Nov 19, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,209
Actual
Start
Jun 1, 2023
Primary completion
Jun 15, 2023
Study completion Jun 18, 2023
Sponsor
- Lead sponsor
- Rawalpindi Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 5, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this systematic review is to assess the effectiveness of neoadjuvant chemotherapy and Trastuzumab in achieving pathological complete response (pCR) in patients with HER2-positive breast cancer. The main questions it aims to answer are: * What is the overall rate of pathological complete response (pCR) in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and Trastuzumab? * Are there any variations in the definition of pCR among the included trials? Participants in the selected clinical trials were HER2-positive breast cancer patients with non-metastatic operable, locally advanced, or inflammatory breast cancer. The main tasks participants were asked to do and the treatments they received are as follows: * Undergo neoadjuvant chemotherapy: Participants received chemotherapy treatment before their primary surgery. * Receive Trastuzumab: Participants were administered Trastuzumab, a targeted therapy for HER2-positive breast cancer. Researchers would compare the group of participants receiving neoadjuvant chemotherapy and Trastuzumab to other groups, if present, to see if there are differences in the rates of pathological complete response (pCR) or other effects.
Conditions
- HER2+ Breast Cancer
Interventions
TrastuzumabDrug
Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response (pCR)Time frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rawalpindi Medical University
Rawalpindi, Punjab Province, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.